Cargando…
Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan
BACKGROUND: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical out...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164570/ https://www.ncbi.nlm.nih.gov/pubmed/35657437 http://dx.doi.org/10.1007/s10157-022-02240-x |
_version_ | 1784720163799564288 |
---|---|
author | Sato, Ryosuke Matsuzawa, Yasushi Ogawa, Hisao Kimura, Kazuo Tsuboi, Nobuo Yokoo, Takashi Okada, Hirokazu Konishi, Masaaki Kirigaya, Jin Fukui, Kazuki Tsukahara, Kengo Shimizu, Hiroyuki Iwabuchi, Keisuke Yamada, Yu Saka, Kenichiro Takeuchi, Ichiro Kashihara, Naoki Tamura, Kouichi |
author_facet | Sato, Ryosuke Matsuzawa, Yasushi Ogawa, Hisao Kimura, Kazuo Tsuboi, Nobuo Yokoo, Takashi Okada, Hirokazu Konishi, Masaaki Kirigaya, Jin Fukui, Kazuki Tsukahara, Kengo Shimizu, Hiroyuki Iwabuchi, Keisuke Yamada, Yu Saka, Kenichiro Takeuchi, Ichiro Kashihara, Naoki Tamura, Kouichi |
author_sort | Sato, Ryosuke |
collection | PubMed |
description | BACKGROUND: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear. METHODS: This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 m(2)) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission. RESULTS: Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality. CONCLUSIONS: On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10157-022-02240-x. |
format | Online Article Text |
id | pubmed-9164570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-91645702022-06-04 Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan Sato, Ryosuke Matsuzawa, Yasushi Ogawa, Hisao Kimura, Kazuo Tsuboi, Nobuo Yokoo, Takashi Okada, Hirokazu Konishi, Masaaki Kirigaya, Jin Fukui, Kazuki Tsukahara, Kengo Shimizu, Hiroyuki Iwabuchi, Keisuke Yamada, Yu Saka, Kenichiro Takeuchi, Ichiro Kashihara, Naoki Tamura, Kouichi Clin Exp Nephrol Original Article BACKGROUND: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear. METHODS: This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 m(2)) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission. RESULTS: Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality. CONCLUSIONS: On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10157-022-02240-x. Springer Nature Singapore 2022-06-03 2022 /pmc/articles/PMC9164570/ /pubmed/35657437 http://dx.doi.org/10.1007/s10157-022-02240-x Text en © The Author(s), under exclusive licence to The Japanese Society of Nephrology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Sato, Ryosuke Matsuzawa, Yasushi Ogawa, Hisao Kimura, Kazuo Tsuboi, Nobuo Yokoo, Takashi Okada, Hirokazu Konishi, Masaaki Kirigaya, Jin Fukui, Kazuki Tsukahara, Kengo Shimizu, Hiroyuki Iwabuchi, Keisuke Yamada, Yu Saka, Kenichiro Takeuchi, Ichiro Kashihara, Naoki Tamura, Kouichi Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title | Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title_full | Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title_fullStr | Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title_full_unstemmed | Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title_short | Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan |
title_sort | chronic kidney disease and clinical outcomes in patients with covid-19 in japan |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164570/ https://www.ncbi.nlm.nih.gov/pubmed/35657437 http://dx.doi.org/10.1007/s10157-022-02240-x |
work_keys_str_mv | AT satoryosuke chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT matsuzawayasushi chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT ogawahisao chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT kimurakazuo chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT tsuboinobuo chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT yokootakashi chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT okadahirokazu chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT konishimasaaki chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT kirigayajin chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT fukuikazuki chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT tsukaharakengo chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT shimizuhiroyuki chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT iwabuchikeisuke chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT yamadayu chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT sakakenichiro chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT takeuchiichiro chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT kashiharanaoki chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan AT tamurakouichi chronickidneydiseaseandclinicaloutcomesinpatientswithcovid19injapan |